Strikingly, the combined inhibition of CDK7 and CDK9 led to an over 80% decrease in proliferation in the prostate cancer and CRPC cells but did not affect the cell lines derived from normal prostate epithelia (Fig. 4B). Here, CDK7 is linked to prostate cancer.